Retro Biosciences is a longevity company aiming to add ten years to healthy human lifespan via cellular reprogramming, autophagy, and plasma-focused programs. Notably backed by Sam Altman.
Biotech📍 Redwood City, CAFounded 2021
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Retro Biosciences going public?
No. Retro Biosciences is private and has not filed to go public. There is no S-1 on file.
What is Retro Biosciences' valuation in 2026?
No confirmed valuation is on record for Retro Biosciences. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Retro Biosciences filed an S-1?
No public S-1 is on file for Retro Biosciences.
Can you buy Retro Biosciences stock?
No. Retro Biosciences is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Retro Biosciences on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Joe Betts-LaCroix
Founded
2021
HQ
Redwood City, CA
IPO Status
private
Fundraising Status
private
Secondary Market
Implied price / share
$14.14
Open interest
4
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Retro Biosciences — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
0% of roles posted in last 30d
Open roles
5
via lever
Product-build share
40%
engineering, research, product, design
Trajectory
tightening
balanced build + GTM — 40% builders vs 60% go-to-market/G&A — scaling both sides.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Scientist/Senior Scientist, Analytical Development & Characterization – Cell TheSenior Research Associate/Associate Scientist, Cell Process Development & ManufaLead, Regulatory Affairs CMC - Cell Therapy & Novel TherapeuticsOpen ApplicationSenior Cytogenetics Technologist - Genomic Stability
Counted from Retro Biosciences's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Joe Betts-LaCroix
Products
Cellular reprogramming
Autophagy and plasma-based longevity programs
Competitors
Altos Labs · NewLimit · Calico
BiotechLongevityAging
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.